Dotttikon abandons Solvias talks, expands own labs
20% hike in capacity by 2H 2013
Dottikon Exclusive Synthesis has announced that it is to increase its development capacities for process development and optimisation at its site in Dottikon, Switzerland, by 20%. This should all be operational in 2H 2013. As a result, talks about acquiring the Synthesis & Catalysis business unit of its compatriot Solvias have been terminated.
The company said that the additional lab units “will be put in place to meet the increasing demand for reliable process development of chemically underdeveloped projects under time pressure to secure subsequent production”. In addition, the company will further strengthen and expand its catalysis capabilities, including high-pressure parallel screening equipment. “By this decision, the board of directors of Dottikon ES confirms the belief in the correctness of the one-site strategy that allows short decision and communication pathways, resulting in fast and effective project development and clear and transparent communication to customers,” it added.
In July, Dottikon confirmed that it had initiated exclusive talks with Solvias about acquiring the Synthesis & Catalysis business unit, which is active in chemical development and small-scale production for APIs, plus high-throughput screening and ligand development in catalysis. This remained at the Rosental in Basel, after Solvias moved to its new location in nearby Kaiseraugst. The Analytical Services and Process Analytical Technology units would not have been affected.